Yajun Xu is currently president of Hongsen Investment Group. She also serves as Senior Advisor for Shangbay Capital, co-founder of Epimab, and board member and advisor on numerous biotech companies in U.S. and China. Previously, she was Senior Vice President of Corporate Development at Shangpharma, Executive Vice President of Biology and Pre-Clinical Service at Chempartner in Shanghai, China. Prior to Joining Shangpharma, Yajun was Director of Inflammation at Millennium Pharmaceuticals and Senior Scientist at BASF Bioresearch (now AbbVie Bioresearch). She received her Ph.D. in Biochemistry at Brandeis University and postdoctoral training at Harvard School of Public Health.
Xu, Yajun
Yajun Xu, PhD
Observer, President, Hongsen
x
Yajun Xu, PhD
Observer, President, Hongsen
Yajun Xu is currently president of Hongsen Investment Group. She also serves as Senior Advisor for Shangbay Capital, co-founder of Epimab, and board member and advisor on numerous biotech companies in U.S. and China. Previously, she was Senior Vice President of Corporate Development at Shangpharma, Executive Vice President of Biology and Pre-Clinical Service at Chempartner in Shanghai, China. Prior to Joining Shangpharma, Yajun was Director of Inflammation at Millennium Pharmaceuticals and Senior Scientist at BASF Bioresearch (now AbbVie Bioresearch). She received her Ph.D. in Biochemistry at Brandeis University and postdoctoral training at Harvard School of Public Health.
